Evidence map›Paper›PMID 40933051›Full record

ArticleFrontiers in neurology2025

Efficacy of single vs. multiple botulinum toxin type A injections for trigeminal neuralgia.

Ying-Ying Xu, Cheng-Wei Guo, He-Jing Chen, Ji-Li Bao, Ying Li, Shu-Yang Ma, Qi-Lin Zhang, Jing Liu, Wei-Feng Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying-Ying Xu *Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Cheng-Wei Guo *Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
He-Jing Chen *Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Ji-Li BaoDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Ying LiDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Shu-Yang MaDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Qi-Lin ZhangDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Jing LiuDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Wei-Feng LuoDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The effectiveness of Botulinum toxin type A (BTX-A) has been established in trigeminal neuralgia (TN). This study aimed to assess the therapeutic efficacy and safety of BTX-A injection within a group of TN patients who have chosen to continue BTX-A therapy. Methods: This was a retrospective medical record-review study. Demographic and clinical features and severity and frequency of pain before and 4 weeks after the BTX-A administration were extracted from the patient files. BTX-A was injected into the painful area subcutaneously and/or submucosally. BTX-A injections were performed by the same physician using the same methods. Pain severity was assessed using the visual analog scale (VAS). The patient's overall response to treatment was assessed using the Patient Global Impression of Change (PGIC). Patients were divided into two groups, single-treatment (TN-S) group and multiple-treatment (TN-M) group, according to the numbers of treatment. Results: Thirty patients were included in this study. We classified 16 (53.33%) as TN-S group and 14 (46.67%) as TN-M group. The median VAS score of all patients was 8 (6.75, 10) before the first treatment and 3 (2, 6.25) after the first treatment ( Conclusion: In summary, BTX-A treatment was effective in TN. Elderly patients and patients with good response to the first treatment were more likely to choose to continue BTX-A multiple-treatments. BTX-A remains effective within a group of TN patients who have chosen to continue BTX-A therapy, but the efficacy decreases to a certain extent after multiple treatments.

Indexed as

botulinum toxin type Aefficacy evaluationmultiple treatmentsrepeated injectiontrigeminal neuralgia

Identifiers

PMID40933051
PMCPMC12417189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.